Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib-Reference-Cited by-同舟云学术

Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

Published:2006-10 Issue:8 Volume:1 Page:837-846
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Clark Gary M.,Zborowski Denni M.,Culbertson Jennifer L.,Whitehead Marlo,Savoie Michelle,Seymour Lesley,Shepherd Frances A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. EGFR and cancer prognosis;Nicholson;Eur J Cancer,2001

2. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival;Veale;Br J Cancer,1993

3. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression;Ohsaki;Oncol Rep,2000

4. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?;Meert;Lung Cancer,2006

5. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis;Meert;Eur Respir J,2002

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of thoracic sympathetic ganglion block as a predictor for response to ketamine infusion therapy and spinal cord stimulation in patients with chronic upper extremity pain;Pain Medicine;2024-05-09

2. Clinical implications and immune implications features of TARS1 in breast cancer;Frontiers in Oncology;2023-08-11

3. Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisions;Best Practice & Research Clinical Rheumatology;2022-12

4. Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply;JAMA Oncology;2022-12-01

5. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB);JAMA Oncology;2022-06-01